A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase

T. Banerjee, J. B. DuHadaway, P. Gaspari, E. Sutanto-Ward, D. H. Munn, A. L. Mellor, W. P. Malachowski, G. C. Prendergast, A. J. Muller

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Agents that interfere with tumoral immune tolerance may be useful to prevent or treat cancer. Brassinin is a phytoalexin, a class of natural products derived from plants that includes the widely known compound resveratrol. Brassinin has been demonstrated to have chemopreventive activity in preclinical models but the mechanisms underlying its anticancer properties are unknown. Here, we show that brassinin and a synthetic derivative 5-bromo-brassinin (5-Br-brassinin) are bioavailable inhibitors of indoleamine 2,3-dioxygenase (IDO), a pro-toleragenic enzyme that drives immune escape in cancer. Like other known IDO inhibitors, both of these compounds combined with chemotherapy to elicit regression of autochthonous mammary gland tumors in MMTV-Neu mice. Furthermore, growth of highly aggressive melanoma isograft tumors was suppressed by single agent treatment with 5-Br-brassinin. This response to treatment was lost in athymic mice, indicating a requirement for active host T-cell immunity, and in IDO-null knockout mice, providing direct genetic evidence that IDO inhibition is essential to the antitumor mechanism of action of 5-Br-brassinin. The natural product brassinin thus provides the structural basis for a new class of compounds with in vivo anticancer activity that is mediated through the inhibition of IDO.

Original languageEnglish (US)
Pages (from-to)2851-2857
Number of pages7
JournalOncogene
Volume27
Issue number20
DOIs
StatePublished - May 1 2008

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Biological Products
Isografts
Neoplasms
Immune Tolerance
Human Mammary Glands
brassinin
Nude Mice
Knockout Mice
Immunity
Melanoma
Breast Neoplasms
T-Lymphocytes
Drug Therapy
Enzymes
Therapeutics
Growth

Keywords

  • IDO
  • INDO
  • Immunotherapy
  • Targeted therapeutics
  • Tryptophan
  • Tumoral immune tolerance

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Banerjee, T., DuHadaway, J. B., Gaspari, P., Sutanto-Ward, E., Munn, D. H., Mellor, A. L., ... Muller, A. J. (2008). A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene, 27(20), 2851-2857. https://doi.org/10.1038/sj.onc.1210939

A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. / Banerjee, T.; DuHadaway, J. B.; Gaspari, P.; Sutanto-Ward, E.; Munn, D. H.; Mellor, A. L.; Malachowski, W. P.; Prendergast, G. C.; Muller, A. J.

In: Oncogene, Vol. 27, No. 20, 01.05.2008, p. 2851-2857.

Research output: Contribution to journalArticle

Banerjee, T, DuHadaway, JB, Gaspari, P, Sutanto-Ward, E, Munn, DH, Mellor, AL, Malachowski, WP, Prendergast, GC & Muller, AJ 2008, 'A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase', Oncogene, vol. 27, no. 20, pp. 2851-2857. https://doi.org/10.1038/sj.onc.1210939
Banerjee, T. ; DuHadaway, J. B. ; Gaspari, P. ; Sutanto-Ward, E. ; Munn, D. H. ; Mellor, A. L. ; Malachowski, W. P. ; Prendergast, G. C. ; Muller, A. J. / A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. In: Oncogene. 2008 ; Vol. 27, No. 20. pp. 2851-2857.
@article{0069a720f97345ba9b71dd269a3c63e3,
title = "A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase",
abstract = "Agents that interfere with tumoral immune tolerance may be useful to prevent or treat cancer. Brassinin is a phytoalexin, a class of natural products derived from plants that includes the widely known compound resveratrol. Brassinin has been demonstrated to have chemopreventive activity in preclinical models but the mechanisms underlying its anticancer properties are unknown. Here, we show that brassinin and a synthetic derivative 5-bromo-brassinin (5-Br-brassinin) are bioavailable inhibitors of indoleamine 2,3-dioxygenase (IDO), a pro-toleragenic enzyme that drives immune escape in cancer. Like other known IDO inhibitors, both of these compounds combined with chemotherapy to elicit regression of autochthonous mammary gland tumors in MMTV-Neu mice. Furthermore, growth of highly aggressive melanoma isograft tumors was suppressed by single agent treatment with 5-Br-brassinin. This response to treatment was lost in athymic mice, indicating a requirement for active host T-cell immunity, and in IDO-null knockout mice, providing direct genetic evidence that IDO inhibition is essential to the antitumor mechanism of action of 5-Br-brassinin. The natural product brassinin thus provides the structural basis for a new class of compounds with in vivo anticancer activity that is mediated through the inhibition of IDO.",
keywords = "IDO, INDO, Immunotherapy, Targeted therapeutics, Tryptophan, Tumoral immune tolerance",
author = "T. Banerjee and DuHadaway, {J. B.} and P. Gaspari and E. Sutanto-Ward and Munn, {D. H.} and Mellor, {A. L.} and Malachowski, {W. P.} and Prendergast, {G. C.} and Muller, {A. J.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1038/sj.onc.1210939",
language = "English (US)",
volume = "27",
pages = "2851--2857",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "20",

}

TY - JOUR

T1 - A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase

AU - Banerjee, T.

AU - DuHadaway, J. B.

AU - Gaspari, P.

AU - Sutanto-Ward, E.

AU - Munn, D. H.

AU - Mellor, A. L.

AU - Malachowski, W. P.

AU - Prendergast, G. C.

AU - Muller, A. J.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Agents that interfere with tumoral immune tolerance may be useful to prevent or treat cancer. Brassinin is a phytoalexin, a class of natural products derived from plants that includes the widely known compound resveratrol. Brassinin has been demonstrated to have chemopreventive activity in preclinical models but the mechanisms underlying its anticancer properties are unknown. Here, we show that brassinin and a synthetic derivative 5-bromo-brassinin (5-Br-brassinin) are bioavailable inhibitors of indoleamine 2,3-dioxygenase (IDO), a pro-toleragenic enzyme that drives immune escape in cancer. Like other known IDO inhibitors, both of these compounds combined with chemotherapy to elicit regression of autochthonous mammary gland tumors in MMTV-Neu mice. Furthermore, growth of highly aggressive melanoma isograft tumors was suppressed by single agent treatment with 5-Br-brassinin. This response to treatment was lost in athymic mice, indicating a requirement for active host T-cell immunity, and in IDO-null knockout mice, providing direct genetic evidence that IDO inhibition is essential to the antitumor mechanism of action of 5-Br-brassinin. The natural product brassinin thus provides the structural basis for a new class of compounds with in vivo anticancer activity that is mediated through the inhibition of IDO.

AB - Agents that interfere with tumoral immune tolerance may be useful to prevent or treat cancer. Brassinin is a phytoalexin, a class of natural products derived from plants that includes the widely known compound resveratrol. Brassinin has been demonstrated to have chemopreventive activity in preclinical models but the mechanisms underlying its anticancer properties are unknown. Here, we show that brassinin and a synthetic derivative 5-bromo-brassinin (5-Br-brassinin) are bioavailable inhibitors of indoleamine 2,3-dioxygenase (IDO), a pro-toleragenic enzyme that drives immune escape in cancer. Like other known IDO inhibitors, both of these compounds combined with chemotherapy to elicit regression of autochthonous mammary gland tumors in MMTV-Neu mice. Furthermore, growth of highly aggressive melanoma isograft tumors was suppressed by single agent treatment with 5-Br-brassinin. This response to treatment was lost in athymic mice, indicating a requirement for active host T-cell immunity, and in IDO-null knockout mice, providing direct genetic evidence that IDO inhibition is essential to the antitumor mechanism of action of 5-Br-brassinin. The natural product brassinin thus provides the structural basis for a new class of compounds with in vivo anticancer activity that is mediated through the inhibition of IDO.

KW - IDO

KW - INDO

KW - Immunotherapy

KW - Targeted therapeutics

KW - Tryptophan

KW - Tumoral immune tolerance

UR - http://www.scopus.com/inward/record.url?scp=42949141286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949141286&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1210939

DO - 10.1038/sj.onc.1210939

M3 - Article

C2 - 18026137

AN - SCOPUS:42949141286

VL - 27

SP - 2851

EP - 2857

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 20

ER -